compound 29 [PMID: 36356320]   Click here for help

GtoPdb Ligand ID: 12313

Compound class: Synthetic organic
Comment: This compound is a receptor tyrosine kinase inhibitor with selectivity for fibroblast growth factor receptors 2 and 3 (FGFR2/3) [2]. It is active at both the wild type kinases and at those with activiating mutations in the gatekeeper region (e.g. FGFR2V564I/L/M/F, FGFR3V555I/L/M/F) that are associated with malignancies such as cholangiocarcinoma and bladder cancer. Erdafitinib, pemigatinib and infigratinib are drugs that are already used clinically to target abberant FGFR signalling in specific solid tumour types. These are all pan-FGFR inhibitors and can cause hyperphosphatemia, most likely via activation of FGFR1 [1,3], so sparing this receptor is hypothesised to improve the toxicity profile of FGFR inhibiting drugs.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 108.46
Molecular weight 447.2
XLogP 2.5
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(c1cncc(c1)c1cnn2c1nc(O[C@@H]1COCC1)c(c2)c1cnn(c1)C(C)C)NC([2H])([2H])[2H]
Isomeric SMILES O=C(NC([2H])([2H])[2H])c1cc(c2c3nc(O[C@@H]4COCC4)c(c4cn(C(C)C)nc4)cn3nc2)cnc1
InChI InChI=1S/C23H25N7O3/c1-14(2)29-11-17(9-26-29)20-12-30-21(28-23(20)33-18-4-5-32-13-18)19(10-27-30)15-6-16(8-25-7-15)22(31)24-3/h6-12,14,18H,4-5,13H2,1-3H3,(H,24,31)/t18-/m0/s1/i3D3
InChI Key XKKGIGFZDVPVNO-NGGDXUQASA-N
References
1. Han X, Yang J, Li L, Huang J, King G, Quarles LD. (2016)
Conditional Deletion of Fgfr1 in the Proximal and Distal Tubule Identifies Distinct Roles in Phosphate and Calcium Transport.
PLoS One, 11 (2): e0147845. [PMID:26839958]
2. Shvartsbart A, Roach JJ, Witten MR, Koblish H, Harris JJ, Covington M, Hess R, Lin L, Frascella M, Truong L et al.. (2022)
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3.
J Med Chem, 65 (22): 15433-15442. [PMID:36356320]
3. Wu AL, Feng B, Chen MZ, Kolumam G, Zavala-Solorio J, Wyatt SK, Gandham VD, Carano RA, Sonoda J. (2013)
Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.
PLoS One, 8 (2): e57322. [PMID:23451204]